| Obesity treatment: novel peripheral targets. | |
| | |
MedLine Citation:
|
PMID: 20002077 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Our knowledge of the complex mechanisms underlying energy homeostasis has expanded enormously in recent years. Food intake and body weight are tightly regulated by the hypothalamus, brainstem and reward circuits, on the basis both of cognitive inputs and of diverse humoral and neuronal signals of nutritional status. Several gut hormones, including cholecystokinin, glucagon-like peptide-1, peptide YY, oxyntomodulin, amylin, pancreatic polypeptide and ghrelin, have been shown to play an important role in regulating short-term food intake. These hormones therefore represent potential targets in the development of novel anti-obesity drugs. This review focuses on the role of gut hormones in short- and long-term regulation of food intake, and on the current state of development of gut hormone-based obesity therapies. |
| | |
Authors:
|
Benjamin C T Field; Owais B Chaudhri; Stephen R Bloom |
Related Documents
:
|
2712967 - Metabolic control of food intake. 12008967 - How to get fat: nutritional mechanisms of seasonal fat accumulation in migratory songbi... 19924617 - Fto - friend or foe? 9521627 - Obese gene expression in porcine adipose tissue is reduced by food deprivation but not ... 23451257 - Moderate heat challenge increased yolk steroid hormones and shaped offspring growth and... 21423777 - Can monkeys make investments based on maximized pay-off? |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: British journal of clinical pharmacology Volume: 68 ISSN: 1365-2125 ISO Abbreviation: Br J Clin Pharmacol Publication Date: 2009 Dec |
Date Detail:
|
Created Date: 2009-12-16 Completed Date: 2010-07-29 Revised Date: 2011-03-03 |
Medline Journal Info:
|
Nlm Unique ID: 7503323 Medline TA: Br J Clin Pharmacol Country: England |
Other Details:
|
Languages: eng Pagination: 830-43 Citation Subset: IM |
Affiliation:
|
Department of Investigative Medicine, Imperial College London, Hammersmith Hospital Campus, London, UK. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Amyloid
/
therapeutic use Anti-Obesity Agents / therapeutic use* Appetite Depressants / therapeutic use* Appetite Regulation / drug effects* Cholecystokinin / therapeutic use Eating / physiology Energy Metabolism / physiology Gastrointestinal Agents / therapeutic use* Ghrelin / therapeutic use Humans Islet Amyloid Polypeptide Obesity / drug therapy* Oxyntomodulin / therapeutic use Pancreatic Polypeptide / therapeutic use Peptide YY / therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/Amyloid; 0/Anti-Obesity Agents; 0/Appetite Depressants; 0/Gastrointestinal Agents; 0/Ghrelin; 0/Islet Amyloid Polypeptide; 0/Oxyntomodulin; 106388-42-5/Peptide YY; 59763-91-6/Pancreatic Polypeptide; 9011-97-6/Cholecystokinin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Recent progress in the genetics of common obesity.
Next Document: Rise in antiobesity drug prescribing for children and adolescents in the UK: a population-based stud...